Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10110752 | 0.88 | HTT (0.54) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL917677 | 0.87 | HTT (0.65) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL10110750 | 0.84 | L3MBTL1 (0.60) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL10110748 | 0.83 | L3MBTL1 (0.54) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL15802599 | 0.83 | DPP8 (0.52) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL7276818 | 0.83 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL15834389 | 0.82 | HTT (0.48) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL15834361 | 0.82 | SIRT2 (0.55) | HTTTGM2SMN1; SMN2CASP1FOLH1 | |
| SCHEMBL6748819 | 0.81 | HTT (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL18254066 | 0.81 | HTT (0.81) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575176-B2 | Heteroaromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575176-B2 | Heteroaromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8124607-B2 | Poly aromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, KCNH1 | HTT 554/4885TGM2 3693/4885LMNA 1285/4885 |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | HTT 723/4885TGM2 4711/4885LMNA 956/4885 |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | HTT 723/4885TGM2 4711/4885LMNA 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.